Delirium

Key messages

  • Despite its prevalence in palliative care, delirium is underdiagnosed, especially hypoactive delirium. [1-2] A high index of clinical suspicion is needed. Diagnosis is important for management, prognostication, and in order to counsel families. [3-4] The onset of delirium is associated with a worsening prognosis. [4-9]
  • Delirium in palliative care patients can be a potentially reversible condition. [10]
  • Delirium is more common in patients with previous cognitive impairment or dementia, which makes identification and assessment more difficult. [11]
  • Delirium is a condition which causes significant distress to patients, families and staff. [4, 12-13] The presence of delirium makes it much harder to assess and treat other problems such as pain or depression. [4]
  • Since delirium symptoms fluctuate, assessment should be part of routine care. Like pain, delirium is most accurately assessed if it is monitored regularly rather than being screened for intermittently. There are a number of validated tools which can be used [14] including the Confusion Assessment Method (CAM) [15-16] and the Nursing Delirium Screening Scale (NuDESC). [17]
  • There is often more than one predisposing and precipitating factor for delirium in palliative care. [10]

Background

Delirium is defined as a condition of disturbed consciousness, with reduced ability to focus, sustain or shift attention. The DSM IV - revised diagnostic criteria [18] for delirium require

  • altered cognition or a perceptual disturbance (which is not better accounted for by dementia),
  • symptoms develop over hours to days and tend to fluctuate during the course of the day, and
  • evidence of an aetiological cause for the delirium.

Delirium may be 

  • hyperactive (presenting with agitation, hyperarousal, and restlessness), or
  • hypoactive (presenting with drowsiness, lethargy and reduced levels of arousal), or
  • a mixed pattern in which the symptoms fluctuate between hyperactive and hypoactive. [19]

Delirium is extremely common in palliative care patients. [10] It becomes more frequent towards the end of life, and is an independent predictor of mortality. [4,7,20] The diagnosis is often missed, or may be confused with depression or dementia. Hypoactive delirium in particular is under-diagnosed and is the most frequent subtype of delirium in palliative care settings. [1,8] 

Delirium may be reversible, although there is evidence that in some patients it can be persistent [21] and associated with longer term cognitive problems. [5,22] Much of the evidence about prognosis and treatment of delirium comes from the aged care and critical care literature. However the focus of care in these populations may be different from that in palliative care, particularly in very advanced disease. [4] In palliative care patients delirium is frequently multifactorial, and when the main precipitant is irreversible, or due to other factors (for example patient wishes, risk or burden of the interventions) the decision may be made not to pursue active investigation.

Factors which should be considered as possible contributors to delirium in a palliative care patient, and treated as appropriate, include:

  • Infection
  • Metabolic and biochemical disorders (eg, renal failure, hypercalcaemia, hyponatraemia, dehydration, hypoxia, hypercapnia)
  • Hepatic encephalopathy
  • Structural cerebral disease (eg, primary or secondary cancer, leptomeningeal disease, radiotherapy to the brain)
  • Medications (eg, psychoactive medications such as benzodiazepines, opioids, corticosteroids, antidepressants, or medications with an anticholinergic effect)
  • Drug withdrawal (eg, alcohol, benzodiazepines, nicotine)
  • Environmental (hospital admission and associated procedures, uncorrected sensory deficits eg, vision and hearing).

Terminal restlessness is a cluster of symptoms. Most often described are a combination of agitation and altered mental state, occurring close to the end of life. There is no agreed definition of this condition. Its relationship with delirium, and its management and potential for reversibility are poorly understood. Assessment must include a consideration of alternative diagnoses. The differential diagnosis for this symptom complex may include: poorly controlled physical symptoms such as pain, itch, urinary retention or faecal impaction in a patient who is obtunded; akathisia, myoclonus and other movement disorders; partial complex seizures; paraneoplastic limbic encephalitis; and PTSD or other psychotic disorder. When it causes distress in a dying patient, sedation may be the appropriate goal of treatment, and antipsychotics and benzodiazepines are currently the mainstay of therapy, but these have not been formally evaluated. [4,23]

Related pages on this topic cover:

Pharmacological management of delirium
Non-pharmacological management of delirium.

Active research areas / controversies

  • It is unclear whether hyperactive and hypoactive delirium have the same pathophysiology, prognostic significance and responses to treatment. [19,24] The pathophysiology, assessment and management of terminal restlessness has not been well studied.
  • Multicomponent intervention studies [25] modify the environment to prevent or reduce the duration of delirium. Whether this approach is likely to be effective in palliative care settings has not yet been studied. However it is likely that the hospitalised elderly population in which it has shown benefit has similarities with many patients in the palliative setting.
  • Placebo-controlled trials are still needed to answer the question of whether and which antipsychotics are effective in the treatment of delirium, which targeted symptoms they impact on, whether they improve delirium resolution, and how they should be titrated. [6,26]
  • The possibility of pharmacological prophylaxis has also been identified in non-palliative care populations, however further work is needed to study agents showing promise. [6-7,27] Medications being trialled include antipsychotics, anticholinesterases, melatonin, and prophylactic gabapentin as an opioid sparing agent. [6,28]
  • A Cochrane review of the role of benzodiazepines in management of delirium found no evidence to support the use of benzodiazepines in the treatment of non-alcohol withdrawal related delirium among hospitalised patients. [29]
  

PubMed Searches

Delirium
Free full text only All citations About these searches
Review collection
  1. Spiller JA, Keen JC. Hypoactive delirium: assessing the extent of the problem for inpatient specialist palliative care. Palliat Med. 2006 Jan;20(1):17-23.
  2. Steis MR, Fick DM. Are nurses recognising delirium? A systematic review. J Gerontol Nurs. 2008 Sep;34(9):40-8.
  3. Schuurmans MJ, Duursma SA, Shortridge-Baggett LM. Early recognition of delirium: review of the literature. J Clin Nurs. 2001 Nov;10(6):721-9.
  4. Leonard M, Agar M, Mason C, Lawlor P. Delirium issues in palliative care settings. J Psychosom Res. 2008 Sep;65(3):289-98.
  5. Jackson JC, Gordon SM, Hart RP, Hopkins RO, Ely EW. The association between delirium and cognitive decline: a review of the empirical literature. Neuropsychol Rev. 2004 Jun;14(2);87-98. 
  6. Bourne RS, Tahir TA, Borthwick M, Sampson EL. Drug treatment of delirium: past, present and future. J Psychosom Res. 2008 Sep;65(3):273-82.
  7. Gagnon PR. Treatment of delirium in supportive and palliative care. Curr Opin Support Palliat Care. 2008 Mar;2(1):60-6.
  8. Breitbart W, Alici Y. Agitation and delirium at the end of life: "We couldn't manage him". JAMA. 2008 Dec 24;300(24): 2898-910, E1.
  9. Hatherill S, Flisher AJ. Delirium in children and adolescents: A systematic review of the literature. J Psychosom Res. 2010 Apr;68(4):337-44. Epub 2010 Jan 12. 
  10. Lawlor PG, Gagnon B, Mancini IL, Pereira JL, Hanson J, Suarez-Almazor ME, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med. 2000 Mar 27;160(6):786-94.
  11. Fick DM, Agostini JV, Inouye SK. Delirium superimposed on dementia: a systematic review. J Am Geriatr Soc. 2002 Oct;50(10):1723-32.
  12. Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics. 2002 May-Jun;43(3):183-94.
  13. O'Malley G, Leonard M, Meagher D, O'Keeffe ST. The delirium experience: a review. J Psychosom Res. 2008 Sep;65(3):223-8.
  14. Hjermstad MJ, Loge JH, Kaasa S. Methods for assessment of cognitive failure and delirium in palliative care patients: implications for practice and research. Palliat Med. 2004 Sep;18(6):494-506.
  15. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990 Dec 15;113(12):941-8.
  16. Wong CL, Holroyd-Leduc J, Simel DL, Straus SE. Does this patient have delirium?: value of bedside instruments. JAMA. 2010 Aug 18;304(7):779-86.
  17. Gaudreau JD, Gagnon P, Harel F, Tremblay A, Roy MA. Fast, systematic, and continuous delirium assessment in hospitalized patients: the nursing delirium screening scale. J Pain Symptom Manage. 2005 Apr;29(4):368-75.
  18. American Psychiatric Association. DSM-IV, diagnostic and statistical manual of mental disorders. 4th ed. Washington: APA; 1994.
  19. de Rooij SE, Schuurmans SJ, van der Mast RC, Levi M. Clinical subtypes of delirium and their relevance for daily clinical practice: a systematic review. Int J Geriatr Psychiatry. 2005 Jul;20(7):609-15.
  20. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005 Sep 1;23(25):6240-8.
  21. Dasgupta M, Hillier LM. Factors associated with prolonged delirium: a systematic review. Int Psychogeriatr. 2010 May;22(3):373-94. Epub 2010 Jan 21.
  22. Cole MG, Ciampi A, Belzile E, Zhong L. Persistent delirium in older hospital patients: a systematic review of frequency and prognosis. Age Ageing. 2009 Jan;38(1):19-26. Epub 2008 Nov 18. 
  23. Kehl KA. Treatment of terminal restlessness: a review of the evidence. J Pain Palliat Care Pharmacother. 2004;18(1):5-30.
  24. Meagher DJ, O’Hanlon D, O’Mahony E, Casey PR, Trzepacz PT. Relationship between symptoms and motoric subtype of delirium. J Neuropsychiatry Clin Neurosci. 2000 Winter;12(1):51-6.
  25. Inouye SK, Bogardus ST Jr, Charpentier PA, Leo-Summers L, Acampora D, Holford TR, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999 Mar 4;340(9):669-76.
  26. Seitz DP, Gill SS, van Zyl LT. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry. 2007 Jan;68(1):11-21.
  27. Siddiqi N, Stockdale R, Britton AM, Holmes J. Interventions for preventing delirium in hospitalised patients. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005563.
  28. Campbell N, Boustani MA, Ayub A, Fox GC, Munger SL, Ott C, Guzman O, Farber M, Ademuyiwa A, Singh R. Pharmacological management of delirium in hospitalized adults--a systematic evidence review. J Gen Intern Med. 2009 Jul;24(7):848-53. Epub 2009 May 8.
  29. Lonergan E, Luxenberg J, Areosa Sastre A. Benzodiazepines for delirium. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006379.

 

Last updated 18 January 2017